Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 20/20 | 0.48 |
| ▸ | PSEN2 | P49810 | 20/20 | 0.48 |
| ▸ | APH1B | Q8WW43 | 20/20 | 0.48 |
| ▸ | NCSTN | Q92542 | 20/20 | 0.48 |
| ▸ | APH1A | Q96BI3 | 20/20 | 0.48 |
| ▸ | PSENEN | Q9NZ42 | 20/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16923575 | 0.86 | PSEN1 (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL6127821 | 0.84 | PSEN1 (0.45) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL18649352 | 0.84 | PSEN1 (0.48) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL22184931 | 0.82 | HCAR1 (0.48) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL6127791 | 0.82 | PSEN1 (0.54) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL9607092 | 0.81 | PSEN1 (0.45) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL16914028 | 0.81 | TLR2 (0.48) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL7923905 | 0.79 | PSEN1 (0.49) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL16255769 | 0.78 | NR2E1 (0.44) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL13081167 | 0.77 | CYP1A2 (0.47) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9598437-B2 | Gamma secretase modulators | MERCK SHARP & DOHME CORP. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160304534-A1 | GAMMA SECRETASE MODULATORS | MERCK SHARP & DOHME LLC | 2016-10-20 | — | — | US | disclosed |
| US-9096582-B2 | Gamma secretase modulators | MERCK SHARP & DOHME CORP (US) | 2015-08-04 | — | — | US | disclosed |
| WO-2015084752-A1 | GAMMA SECRETASE MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2015-06-11 | — | — | WO | disclosed |
| US-20140296311-A1 | GAMMA SECRETASE MODULATORS | MERCK SHARP & DOHME LLC | 2014-10-02 | — | — | US | disclosed |
| US-8809318-B2 | Gamma secretase modulators | MERCK SHARP & DOHME CORP. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8759337-B2 | Gamma secretase modulators | MERCK SHARP & DOHME CORP. (US) | 2014-06-24 | — | — | US | disclosed |
| US-8580956-B2 | Gamma secretase modulators | MERCK SHARP & DOHME CORP. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8487099-B2 | Gamma secretase modulators | MERCK SHARP & DOHME CORP. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8450343-B2 | Gamma secretase modulators | SCHERING CORPORATION | 2013-05-28 | — | — | US | disclosed |
| US-20110263529-A1 | GAMMA SECRETASE MODULATORS | MERCK SHARP & DOHME CORP. | 2011-10-27 | — | — | US | disclosed |
| US-20110027264-A1 | GAMMA SECRETASE MODULATORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | SCHERING CORPORATION | 2011-02-03 | — | — | US | disclosed |
| US-20110015190-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2011-01-20 | — | — | US | disclosed |
| WO-2010147973-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2010-12-23 | — | — | WO | disclosed |
| US-20100298372-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2010-11-25 | — | — | US | disclosed |
| US-20100298381-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2010-11-25 | — | — | US | disclosed |
| US-20100297128-A1 | GAMMA SECRETASE MODULATORS | MERCK SHARP & DOHME LLC | 2010-11-25 | — | — | US | disclosed |
| US-20100256128-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2010-10-07 | — | — | US | disclosed |
| US-20100247514-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2010-09-30 | — | — | US | disclosed |
| WO-2010075203-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304534-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | PSEN1 3/4885PSEN2 4/4885APH1B 9/4885 |
| US-20100297128-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | PSEN1 3/4885PSEN2 9/4885APH1B 7/4885 |
| US-20100247514-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | PSEN1 3/4885PSEN2 8/4885APH1B 9/4885 |
| US-20100298372-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | PSEN1 3/4885PSEN2 8/4885APH1B 5/4885 |
| US-20100256128-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | PSEN1 3/4885PSEN2 8/4885APH1B 9/4885 |
| US-20110263529-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | PSEN1 3/4885PSEN2 8/4885APH1B 9/4885 |
| US-20110027264-A1 | GAMMA SECRETASE MODULATORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BACE1, BACE2, PSEN1 | PSEN1 3/4885PSEN2 5/4885APH1B 7/4885 |
| US-20100298381-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSENEN | PSEN1 4/4885PSEN2 9/4885APH1B 7/4885 |
| US-20110015190-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | PSEN1 3/4885PSEN2 4/4885APH1B 6/4885 |
| US-20140296311-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | PSEN1 3/4885PSEN2 5/4885APH1B 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.